In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAME: Victrelis (Merck)
- INDICATIONS: Chronic hepatitis C
- CLASS: CYP3A4 inhibitor, Direct-acting antiviral, Hepatitis C virus NS3/4A protease inhibitor
- HALF-LIFE: 3 hours
- FDA APPROVAL DATE: 05/13/2011
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alfuzosin, Alprazolam, Amiodarone, Atorvastatin, Bepridil, Bosentan, Brigatinib, Budesonide, Buprenorphine, Cabozantinib, Carbamazepine, Cisapride, Clarithromycin, Colchicine, Copanlisib, Cyclosporine, Dasatinib, Desipramine, Dexamethasone, Digoxin, Dihydroergotamine, Drospirenone, Efavirenz, Ergonovine, Ergotamine, Estradiol, Felodipine, Flecainide, Flibanserin, Fluticasone Propionate, Gefitinib, Itraconazole, Ketoconazole, Lomitapide, Lovastatin, Methadone, Methylergonovine, Midazolam, Midostaurin, Mifepristone, Neratinib, Nicardipine, Nifedipine, Olaparib, Pazopanib, Phenobarbital, Phenytoin, Pimozide, Ponatinib, Posaconazole, Propafenone, Quinidine, Ribociclib, Rifabutin, Rifampin, Ritonavir, Ruxolitinib, Salmeterol, Sildenafil, Simvastatin, Sirolimus, St John's Wort, Tacrolimus, Tadalafil, Trazodone, Triazolam, Vardenafil, Vorapaxar, Voriconazole, Warfarin - PREGNANCY: boceprevir is pregnancy category B but must not be used in monotherapy
- See adverse reactions attributed to class:
Must be used in combination with PEG-interferon and ribavirin (see separate entries)
Combination treatment is contra-indicated in pregnant women and men whose female partners are pregnant because of the risks for birth defects and fetal death associated with ribavirin, or in coadministration with drugs that are highly dependent on CYP3A4/5 for clearance, or with potent CYP3A4/5 inducers.
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
